Clinical trials: Recurrence Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
Hepatocellular carcinoma, the most common type of primary liver cancer, can recur after liver resection or thermal ablation performed with curative intent.
- Trial name
- HCC-AI-RECLAIM (NCT07732504)
- Testing
- Artificial Intelligence-Guided Risk-Adapted Surveillance, Fixed-Interval Surveillance
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma Recurrent
A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
To observe and compare the short-term and long-term oncological outcome of laparoscopic hepatectomy and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma .
- Trial name
- NCT03313648
- Testing
- Laparoscopic Hepatectomy, Radiofrequency Ablation
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Southwest Hospital, China
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00009893
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 19 sites in United States
- Volunteers
- 42 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Hepatocellular Carcinoma
Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence
HBV DNA integration has been found in the chromosomes of about 90% of HBV-related HCC and the integration site is unique to individual HCC.
- Trial name
- NCT05823584
- Where
- Taiwan
- Volunteers
- 207 people
- Sponsor
- TCM Biotech International Corp.
Hepatocellular Carcinoma
Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
To compare the safety and efficacy of unmodified RAK cells and anti-TIM-3 blocked autologous RAK cells in preventing postoperative recurrence of HCC by postoperative TACE therapy combined with immune cell therapy.
- Trial name
- NCT05738980
- Testing
- Autologous RAK cells
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Beijing Hospital
Hepatocarcinoma
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after…
- Trial name
- NCT06900478
- Testing
- Icariin Soft Capsules+TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hua Li
Hepatocellular Carcinoma, Liver Transplant; Complications
Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation
The use of devices for liver grafts perfusion before transplantation, either hypothermic (HOPE) or normothermic (NMP), is rapidly spreading thanks to the promising results obtained so far in terms of graft survival and…
- Trial name
- NCT06236568
- Testing
- D-HOPE machine perfusion, Liver transplantation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Carcinoma, Hepatocellular
Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection
Hepatocellular carcinoma (HCC) is the sixth most common malignancies worldwide and the second leading cause of cancer-related death.
- Trial name
- NCT02738697
- Testing
- Adjuvant chemotherapy, Follow-up
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Sun Yat-sen University
HCC, Adjuvant Therapy
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities.
- Conditions
- HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor
- Trial name
- NCT07379489
- Testing
- PD-1 Inhibitors
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
High Risk of Recurrence
Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma
The challenge of LDLT to HCC is that tumors with a high risk of recurrence have a high rate of recurrence after liver transplantation, and there is no appropriate treatment to prevent HCC recurrence after transplantation in these…
- Trial name
- NCT06327269
- Testing
- Lenvatinib 10 mg
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Recurrent Liver Cancer, Primary Liver Cancer
Recurrent Liver Cancer: Reconceptualization and Reevaluation
The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer.
- Trial name
- NCT06430983
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Liver Transplant Disorder, Liver Cancer
Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Identifying patients at high risk for recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) represents a challenging issue.
- Conditions
- Liver Transplant Disorder, Liver Cancer, Recurrent Cancer
- Trial name
- TRAIN-AI (NCT05200195)
- Testing
- Liver transplantation
- Where
- Italy
- Volunteers
- 4,026 people
- Sponsor
- European Hepatocellular Cancer Liver Transplant Group
HCC
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy…
- Trial name
- NCT07009470
- Testing
- Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tongji Hospital
HCC
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
Radiofrequency ablation (RFA)can be curative with small localized HCCs up to 5 cm in diameter. However, the long-term prognosis is not satisfactory due to the high incidence of recurrence.Multimodality treatments are needed to…
- Trial name
- NCT02187081
- Testing
- radiofrequency ablation plus Sorafenib, Radiofrequency ablation
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Southwest Hospital, China
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Hepatocellular Carcinoma (HCC)
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
This study aims to compare the safety and tolerability of cadonilimab applied after curative hepatectomy for hepatocellular carcinoma combined with high - risk recurrent factors.
- Trial name
- NCT06851104
- Testing
- Cadonilimab (AK104)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Carcinom, Hepatocellular
Adjuvant Everolimus in High-Risk Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial)
"Hepatic resection is the primary curative treatment for patients with a single, liver-confined hepatocellular carcinoma (HCC) without cirrhosis and is also considered in patients with cirrhosis if residual liver function is…
- Trial name
- NCT06972758
- Testing
- Certirobell®
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University